Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
A new technique that sterilizes male mosquito through radiation shows promise in fighting mosquito-borne illnesses, including Zika, dengue and chikungunya. Soon, health experts plan to test the technique as part of global health efforts to control these diseases.
Scientists funded by the National Institutes of Health have developed an investigational vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa.
There is currently no vaccine for the Lassa arenavirus, which causes Lassa fever. This hemorrhagic fever, endemic in West Africa, infects up to 300,000 people each year.
The Ebola virus disease (EVD) is a deadly infection that is highly contagious. It has taken thousands of lives across history, with a number of outbreaks mostly happening in West Africa. In the worse outbreak, between 2014 and 2016, there had been 28,616 cases of EVD, 11,310 of whom had died in the continent. Overseas, there had been 36 cases and 15 deaths.
This particular inquiry pertains to CCR5 - a gene which has lately been on the focuses of research worldwide. In particular, CCR5 deletion was used in China to perform the first ever genetic editing on human embryos. It's also known that a CCR5-Δ32 mutation can make people immune to HIV.
In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa.
A second experimental Ebola vaccine made by Johnson & Johnson will soon undergo clinical trials in the Ebola affected Democratic Republic of the Congo (DRC) announced health officials. The second round of vaccinations is to begin middle of October this year.
Researchers have come one step closer to understanding how our immune system responds to acute dengue fever, a disease that has affected hundreds of thousands of people in Southeast Asia this summer alone.
Control and prevention of Aedes-transmitted viruses, such as dengue, chikungunya, or Zika relies heavily on vector control approaches. Given the effort and cost involved in implementation of vector control, targeting of control measures is highly desirable. However, it is unclear to what extent the effectiveness of highly focal and reactive control measures depends on the commuting and movement patterns of humans.
Ebola, the deadly viral infection, is spreading in Congo and the World Health Organization (WHO) has announced it as an international health emergency. Speaking in front of reporters, WHO Director-General Tedros Adhanom Ghebreyesus gave updates on the situation in the Central African country.
After smouldering in the Democratic Republic of Congo (DRC) for almost a year, killing near 1,000 people, the deadly Ebola virus crossed the border to Uganda in June 2019. This virus causes sudden high fever and sore throat, with severe weakness and muscle pain.
Dengue fever stopped spreading in an Australian city, called Townsville, after an army of mosquitoes infected with the Wolbachia bacterium was released on it.
The U.S. Food and Drug Administration announced today the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in endemic areas.
The University of Texas Medical Branch at Galveston, Profectus Biosciences, Vanderbilt University Medical Center, Mapp Biopharmaceutical and Genevant Sciences Corp. have been awarded up to $35 million to advance the development of rapid-acting vaccines and broad-spectrum treatments of the highly-lethal hemorrhagic fever viruses Ebola and Marburg.
The National Institute of Allergy and Infectious Diseases has awarded an international consortium led by Albert Einstein College of Medicine, part of Montefiore, a five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.
About 40 percent of the global population is at risk for contracting dengue - the most important mosquito-borne viral infection and a close "cousin" of the Zika virus - and yet, no effective treatment or safe licensed vaccine exists.
Staten Island residents have another reason to apply insect repellent and obsessively check for ticks this spring and summer: the population of a new, potentially dangerous invasive pest known as the Asian longhorned tick has grown dramatically across the borough, according to Columbia University researchers.
It was recently reported that the number of Ebola cases in the Democratic Republic of Congo has surpassed 1,000, making it the second-worst outbreak in history after the 2014 outbreak in West Africa in which 29,000 people were infected and more than 11,000 died.
Dr Paulo Rocha from the University of Bath's Department of Electronic & Electrical Engineering is developing a low-cost integrative sensing tool for early detection of Dengue virus, using a novel platform containing electrical sensors to investigate the behavior of human cells infected with Dengue virus.
Dubbed ‘Disease X’, scientists believe a future epidemic of the influenza virus could cause millions of deaths worldwide.